ArticlePloS one2015
Preclinical TSPO Ligand PET to Visualize Human Glioma Xenotransplants: A Preliminary Study.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Bispecific Antibodies in Glioblastoma: Mechanistic Advances, Delivery Innovations, and Translational Challenges in Overcoming Immune Escape.International journal of medical sciences · 2025Review
- Deciphering sources of PET signals in the tumor microenvironment of glioblastoma at cellular resolution.Science advances · 2023Article
- Molecular imaging of tumor-associated macrophages in cancer immunotherapy.Therapeutic advances in medical oncology · 2022Review
- Imaging of the glioma microenvironment by TSPO PET.European journal of nuclear medicine and molecular imaging · 2021Review
- Article
- Imaging temozolomide-induced changes in the myeloid glioma microenvironment.Theranostics · 2021Article
- A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.Theranostics · 2021Review
- Selective, high-contrast detection of syngeneic glioblastoma in vivo.Scientific reports · 2020Article
- In vivo monitoring of remnant undifferentiated neural cells following human induced pluripotent stem cell-derived neural stem/progenitor cells transplantation.Stem cells translational medicine · 2020Article
- TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma.Neuro-oncology · 2019Article
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[Molecular imaging and biology · 2019Article
- TSPO PET usingEuropean journal of nuclear medicine and molecular imaging · 2017Article
- TSPO PET for glioma imaging using the novel ligandEuropean journal of nuclear medicine and molecular imaging · 2017Article
- Evaluation of TSPO PET Ligands [Molecular imaging and biology · 2017Article
- Study on the therapeutic effect of neural progenitor cells in mice of a glioma murine model.Oncology letters · 2016Article
- TSPO expression in brain tumours: is TSPO a target for brain tumour imaging?Clinical and translational imagingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Current positron emission tomography (PET) imaging biomarkers for detection of infiltrating gliomas are limited. Translocator protein (TSPO) is a novel and promising biomarker for glioma PET imaging. To validate TSPO as a potential target for molecular imaging of glioma, TSPO expression was assayed in a tumor microarray containing 37 high-grade (III, IV) gliomas. TSPO staining was detected in all tumor specimens. Subsequently, PET imaging was performed with an aryloxyanilide-based TSPO ligand, [18F]PBR06, in primary orthotopic xenograft models of WHO grade III and IV gliomas. Selective uptake of [18F]PBR06 in engrafted tumor was measured. Furthermore, PET imaging with [18F]PBR06 demonstrated infiltrative glioma growth that was undetectable by traditional magnetic resonance imaging (MRI). Preliminary PET with [18F]PBR06 demonstrated a preferential tumor-to-normal background ratio in comparison to 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG). These results suggest that TSPO PET imaging with such high-affinity radiotracers may represent a novel strategy to characterize distinct molecular features of glioma growth, as well as better define the extent of glioma infiltration for therapeutic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.